Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer
Nikhil Shukla, Nasser H. Hanna
Lung Cancer Targets and Therapy (2021) Vol. Volume 12, pp. 51-60
Open Access | Times Cited: 26

Showing 1-25 of 26 citing articles:

Multidisciplinary meeting review in nonsmall cell lung cancer: a systematic review and meta-analysis
Rob G. Stirling, Amelia Harrison, Joanna Huang, et al.
European Respiratory Review (2024) Vol. 33, Iss. 172, pp. 230157-230157
Open Access | Times Cited: 6
Neoadjuvant Intratumoral MBT(A) Immunotherapy Prevents Distant Metastases and Recurrence in Murine Models
Ondřej Uher, Katerina Hadrava Vanova, Rachael N. Labitt, et al.
Cancer Letters (2025), pp. 217464-217464
Closed Access
A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy
Angel A Justiz-Vaillant, Bijay Raj Pandit, Chandrashekhar Unakal, et al.
Antibodies (2025) Vol. 14, Iss. 2, pp. 35-35
Open Access
Clinical Applications of Endobronchial Ultrasound (EBUS) Scope: Challenges and Opportunities
Davide Biondini, Mariaenrica Tinè, Umberto Semenzato, et al.
Diagnostics (2023) Vol. 13, Iss. 15, pp. 2565-2565
Open Access | Times Cited: 9
Construction of aptamer-siRNA chimera and glutamine modified carboxymethyl-β-cyclodextrin nanoparticles for the combination therapy against lung squamous cell carcinoma
Yanfei Hao, Jintao Yang, Dongxu Liu, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 174, pp. 116506-116506
Open Access | Times Cited: 3
EGFR mutation prevalence, real-world treatment patterns, and outcomes among patients with resected, early-stage, non-small cell lung cancer in Canada
M. Sara Kuruvilla, Geoffrey Liu, Iqra Syed, et al.
Lung Cancer (2022) Vol. 173, pp. 58-66
Closed Access | Times Cited: 13
STK11/LKB1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial
Jean Baptiste Oudart, Simon Garinet, Caroline Léger, et al.
Lung Cancer (2024) Vol. 190, pp. 107508-107508
Open Access | Times Cited: 2
Real-life long-term outcomes of upfront surgery in patients with resectable stage I-IIIA non-small cell lung cancer
Marko Bitenc, Tanja Čufer, Izidor Kern, et al.
Radiology and Oncology (2022) Vol. 56, Iss. 3, pp. 346-354
Open Access | Times Cited: 9
Immune microenvironment analysis and novel biomarkers of early-stage lung adenocarcinoma evolution
Jun Liu, Yaxin Ji, Xiao‐Dan Weng, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 5
Real-world study of disease-free survival & patient characteristics associated with disease-free survival in early-stage non-small cell lung cancer: A retrospective observational study
Anne Shah, Jon Apple, Andrew J. Belli, et al.
Cancer Treatment and Research Communications (2023) Vol. 36, pp. 100742-100742
Open Access | Times Cited: 5
Prognosis of recurrence after complete resection in early-stage lung adenocarcinoma based on molecular alterations: a systematic review and meta-analysis
Chu Zhou, Zhongying Jing, Wei Liu, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 5
Immune Checkpoint Inhibitor Score Predicts Survival Benefit of Immunotherapy in Patients with Non-small Cell Lung Cancer
Da Hyun Kang, Chang‐Min Choi, Cheol‐Kyu Park, et al.
Tuberculosis & respiratory diseases (2024) Vol. 87, Iss. 4, pp. 483-493
Open Access | Times Cited: 1
Case report: The effect of induction targeted therapies in stage III driver mutants non-small cell lung cancer
Waleed Kian, Bilal Krayim, Betsy Giles, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 1
Pathologic responses to neoadjuvant chemoimmunotherapy in primary limited‐stage small‐cell lung cancer
Meng Lu, Ran Zhang, Lisha Qi, et al.
Thoracic Cancer (2022) Vol. 13, Iss. 22, pp. 3208-3216
Open Access | Times Cited: 6
Tumor glycolytic heterogeneity improves detection of regional nodal metastasis in patients with lung adenocarcinoma
Kun‐Han Lue, Sung‐Chao Chu, Ling-Yi Wang, et al.
Annals of Nuclear Medicine (2021) Vol. 36, Iss. 3, pp. 256-266
Closed Access | Times Cited: 8
Cost-effectiveness of adjuvant atezolizumab versus best supportive care in the treatment of patients with resectable early-stage non-small cell lung cancer and overexpression of PD-L1
Vicente Escudero‐Vilaplana, Roberto Collado‐Borrell, Javier de Castro, et al.
Journal of Medical Economics (2023) Vol. 26, Iss. 1, pp. 445-453
Open Access | Times Cited: 3
Role of Adjuvant Chemotherapy in Early-Stage Combined Small Cell Lung Cancer
Arian Mansur, Alexandra L. Potter, Alexandra T. Nees, et al.
The Annals of Thoracic Surgery (2023) Vol. 116, Iss. 6, pp. 1142-1148
Closed Access | Times Cited: 3
Clinical Applications of Endobronchial Ultrasound: Challenges and Opportunities
Davide Biondini, Mariaenrica Tinè, Umberto Semenzato, et al.
(2023)
Open Access | Times Cited: 3
Cáncer de pulmón
Carlos Manzano, Álvaro Fuentes-Martín, María Zuil, et al.
Open Respiratory Archives (2023) Vol. 5, Iss. 3, pp. 100264-100264
Open Access | Times Cited: 3
EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?
Paul Hofman
Cells (2021) Vol. 10, Iss. 8, pp. 2157-2157
Open Access | Times Cited: 6
Concomitant Statins and the Survival of Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors: A Meta-Analysis
Lei Zhang, Hong Wang, Jizheng Tian, et al.
International Journal of Clinical Practice (2022) Vol. 2022, pp. 1-10
Open Access | Times Cited: 4
Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches
Chuan‐Hsin Chang, Yue‐Cune Chang
International Journal of Environmental Research and Public Health (2022) Vol. 19, Iss. 21, pp. 14324-14324
Open Access | Times Cited: 3
Integrating Durvalumab with Neoadjuvant Chemoradiation and Surgery in Patients with Borderline Resectable Stage III Non-Small Cell Lung Cancer: A Retrospective Case Series
Akram Saad, Sarit Appel, Alon Ben‐Nun, et al.
Research Square (Research Square) (2024)
Open Access
Neoadjuvant Therapy in Robotic Lung Surgery: Elevating Surgical Complexity Without Compromising Outcomes
Inés Serratosa, Carlos Déniz, Camilo Moreno, et al.
Cancers (2024) Vol. 16, Iss. 23, pp. 3938-3938
Open Access
Pathologic Responses to Neoadjuvant Chemoimmunotherapy in Primary Limited-Stage Small Cell Lung Cancer
Meng Lu, Ran Zhang, Lisha Qi, et al.
Research Square (Research Square) (2022)
Open Access
Page 1 - Next Page

Scroll to top